G and A expense for the fiscal year ended March 31, 2024 was $37,300,000 compared with $34,700,000 for the previous fiscal year. The biggest moving parts in the net increase of $2,700,000 were due to increases in headcount. Other expense for the year ended March 31, 2024 and March 31, 2023 were losses of 1,300,000 and $7,300,000 respectively. The $6,000,000 improvement was mainly due to the $7,100,000 year on year decrease in non product related litigation, an additional $1,100,000 of interest income and $700,000 pickup from the change in fair value of our warrant liability, partially offset by an increase in interest expense of $2,900,000 For the year ended March 31, 2024, the company recorded a net loss of $64,300,000 of which $60,200,000 or $1.82 per share was attributable to the shareholders of Beyond Air Inc, compared with a net loss of $59,400,000 or $1.86 a share for the fiscal quarter ended March 31, 2023. Net cash burn in the quarter ended March 31, 2024 was $12,800,000 We continue to expand our pool of lung fit devices in addition to making payments on our VCAAP study, continue to work on the development of our transport ready device, human trials in BEYOND Cancer and advances in our autism program.